Ameriprise Financial Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Ameriprise Financial Inc

  • $388 Billion
  • Q2 2025

A detailed history of Ameriprise Financial Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 267,027 shares of ARWR stock, worth $4.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
267,027
Previous 286,231 6.71%
Holding current value
$4.75 Million
Previous $3.65 Million 15.72%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$9.99 - $16.97 $191,847 - $325,891
-19,204 Reduced 6.71%
267,027 $4.22 Million
Q1 2025

May 14, 2025
BUY
$12.74 - $21.53 $780,235 - $1.32 Million
61,243 Added 27.22%
286,231 $3.65 Million
Q4 2024

Feb 14, 2025
BUY
$17.7 - $26.34 $101,456 - $150,980
5,732 Added 2.61%
224,988 $4.23 Million
Q3 2024

Nov 14, 2024
SELL
$19.36 - $29.54 $10 Million - $15.3 Million
-518,944 Reduced 70.3%
219,256 $4.24 Million
Q2 2024

Aug 14, 2024
SELL
$21.87 - $28.24 $5.67 Million - $7.32 Million
-259,097 Reduced 25.98%
738,200 $19.2 Million
Q1 2024

May 15, 2024
BUY
$27.21 - $39.48 $1.87 Million - $2.71 Million
68,697 Added 7.4%
997,297 $28.5 Million
Q4 2023

Feb 14, 2024
BUY
$21.2 - $31.03 $4.98 Million - $7.29 Million
234,984 Added 33.88%
928,600 $28.4 Million
Q3 2023

Nov 14, 2023
BUY
$26.2 - $36.08 $6.35 Million - $8.74 Million
242,277 Added 53.68%
693,616 $18.6 Million
Q2 2023

Aug 14, 2023
SELL
$25.16 - $41.38 $375,865 - $618,175
-14,939 Reduced 3.2%
451,339 $16.1 Million
Q1 2023

May 15, 2023
SELL
$23.68 - $38.51 $931,973 - $1.52 Million
-39,357 Reduced 7.78%
466,278 $11.8 Million
Q4 2022

Feb 14, 2023
SELL
$28.0 - $40.56 $703,864 - $1.02 Million
-25,138 Reduced 4.74%
505,635 $20.5 Million
Q3 2022

Nov 14, 2022
SELL
$29.63 - $48.31 $221,039 - $360,392
-7,460 Reduced 1.39%
530,773 $17.5 Million
Q2 2022

Aug 15, 2022
BUY
$27.79 - $50.61 $58,414 - $106,382
2,102 Added 0.39%
538,233 $19 Million
Q1 2022

May 16, 2022
SELL
$39.62 - $69.97 $318,584 - $562,628
-8,041 Reduced 1.48%
536,131 $24.7 Million
Q4 2021

Feb 14, 2022
BUY
$58.09 - $82.51 $2.79 Million - $3.96 Million
47,975 Added 9.67%
544,172 $36.1 Million
Q3 2021

Nov 15, 2021
SELL
$58.38 - $84.96 $114,775 - $167,031
-1,966 Reduced 0.39%
496,197 $31 Million
Q2 2021

Aug 16, 2021
BUY
$62.15 - $90.32 $301,862 - $438,684
4,857 Added 0.98%
498,163 $41.3 Million
Q1 2021

May 17, 2021
BUY
$61.35 - $90.47 $1.08 Million - $1.59 Million
17,624 Added 3.7%
493,306 $32.7 Million
Q4 2020

Feb 12, 2021
SELL
$43.82 - $85.37 $2.56 Million - $4.98 Million
-58,377 Reduced 10.93%
475,682 $36.5 Million
Q3 2020

Nov 16, 2020
BUY
$33.21 - $51.27 $3.23 Million - $4.99 Million
97,361 Added 22.29%
534,059 $23 Million
Q2 2020

Aug 14, 2020
BUY
$26.12 - $43.27 $2.39 Million - $3.96 Million
91,533 Added 26.52%
436,698 $18.9 Million
Q1 2020

May 15, 2020
SELL
$20.56 - $63.12 $334,490 - $1.03 Million
-16,269 Reduced 4.5%
345,165 $9.93 Million
Q4 2019

Feb 14, 2020
SELL
$28.14 - $73.01 $5.01 Million - $13 Million
-177,931 Reduced 32.99%
361,434 $22.9 Million
Q3 2019

Nov 14, 2019
BUY
$26.26 - $34.86 $436,204 - $579,059
16,611 Added 3.18%
539,365 $15.2 Million
Q2 2019

Aug 14, 2019
BUY
$17.43 - $28.82 $9.11 Million - $15.1 Million
522,754 New
522,754 $13.9 Million
Q1 2019

May 15, 2019
SELL
$12.05 - $20.18 $1,144 - $1,917
-95 Closed
0 $0
Q4 2018

Feb 14, 2019
SELL
$10.74 - $19.7 $805,167 - $1.48 Million
-74,969 Reduced 99.87%
95 $1,000
Q3 2018

Nov 14, 2018
BUY
$14.0 - $20.3 $889,896 - $1.29 Million
63,564 Added 552.73%
75,064 $1.44 Million
Q2 2018

Aug 14, 2018
BUY
$6.37 - $14.02 $73,255 - $161,230
11,500 New
11,500 $156,000

Others Institutions Holding ARWR

# of Institutions
318
Shares Held
99M
Call Options Held
444K
Put Options Held
568K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $1.88B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email